Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Ashani Tanuja Weeraratna, Ph.D.

Headshot of Ashani Tanuja Weeraratna
  • E.V. McCollum Professor and Chair, Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health
  • Professor of Oncology


Dr. Weeraratna is the E.V. McCollum Chair of Biochemistry and Molecular Biology at the Johns Hopkins School of Public Health, a Bloomberg Distinguished Professor, and Co-Program Leader of the Cancer Invasion and Metastasis Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine. Prior to joining Johns Hopkins, she was the Ira Brind Professor and Co-Program Leader, Immunology, Microenvironment & Metastasis Program Member at the Wistar Institute. Born in Sri Lanka and raised in Southern Africa, Weeraratna first came to the United States in 1988 to study biology at St. Mary’s College of Maryland. She earned a Ph.D. in Molecular and Cellular Oncology at the Department of Pharmacology of George Washington University Medical Center. From 1998 to 2000, she was a post-doctoral fellow at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Oncology Center, before joining the National Human Genome Research Institute as a staff scientist. In 2003, she moved to the National Institute on Aging, where she started her own research program, before joining the Wistar Institute from 2011-2019.

Dr. Weeraratna is an expert in melanoma metastasis, Wnt signaling, and aging, and her research focuses heavily on the effects of the tumor microenvironment on metastasis and therapy resistance. She is one of the first to study how the aging microenvironment guides metastasis and therapy resistance in melanoma. Her studies encompass biophysical changes that affect the ability of both tumor and immune cells to migrate, that affect vasculature integrity thus dictating routes of metastasis, and also secreted changes that drive metastatic signaling and response to therapy. The Weeraratna laboratory has also undertaken a global analysis of how the aged microenvironment promotes metastasis, using a unique resource of normal skin fibroblasts from healthy donors of differing ages, proteomics analysis, and animal models. The clinical implications of these data may also result in a change in clinical practice, as they are finding age-related differences in responses to both targeted and immunotherapy. Dr. Weeraratna is using these proteomics data to guide further studies on how the aging microenvironment affects tumor dormancy and cellular metabolism.
Through speaking engagements and social media, Dr. Weeraratna diligently promotes skin safety, from urging proper sunscreen use to regular mole checks, as well as the dangers of indoor tanning. She is also a fierce champion of and a mentor for junior faculty, women and people of color in science. more


  • E.V. McCollum Professor and Chair, Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health
  • Bloomberg Distinguished Professor
  • Professor of Oncology

Departments / Divisions

  • Oncology - Cancer Genetics and Epigenetics



  • Ph.D.; George Washington University (District of Columbia) (1998)

Research & Publications

Selected Publications

Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, Webster MR, Kugel CH, Ecker BL, Caino MC, Kossenkov AV, Tang HY, Frederick DT, Flaherty KT, Xu X, Liu Q, Gabrilovich DI, Herlyn M, Blair IA, Schug ZT, Speicher DW, Weeraratna AT. Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2. Cancer Discovery. 2020 Jun 4:CD-20-0329. doi: 10.1158/2159-8290.CD-20-0329. Online ahead of print.

Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89-106. doi:10.1038/s41568-019-0222-9

Webster MR, Fane M, Alicea GM, Basu S, Kossenkov AV, Douglass SM, Kaur A, Ecker BL, Ndoye A, Kugel, CH III, Valiga A, Palmer J, Liu Q, Xu X, Fan X, Wu H, Xu W, Zheng C, Karakousis G, Amaravadi R, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Ying JW, Schucter LM, Herlyn M, Murphy ME, and Weeraratna AT. 2020.  Paradoxical role for wild type p53 in driving therapy resistance in melanoma. Molecular Cell, 77(3):633-644.e5.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel III CH, Dang VM, Appleton J, O’Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang H-Y, Yin X, Wood III WH, Lehrmann E,  Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, and Weeraratna AT. 2016.sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-254. PMCID: PMC4833579.

B.L. Ecker, A. Kaur, S. Douglass, M.R. Webster, F.V. Almeida, A.J. Sinnamon, M.G. Neuwirth, A. M. Ndoye, G.M. Alicea, M. Fane, X. Xu, G.C. Karakousis, Weeraratna AT. Age-Related Changes in Lymphatic Permeability May Dictate Routes of Melanoma Metastasis. Cancer Discovery, 9(1):82-95

Is this you? Edit Profile
back to top button